Atenolol tablets (Tablets) Instructions for Use
ATC Code
C07AB03 (Atenolol)
Active Substance
Atenolol (Rec.INN registered by WHO)
Clinical-Pharmacological Group
Beta1-adrenoblocker
Pharmacotherapeutic Group
Selective beta1-adrenergic blocker
Pharmacological Action
Cardioselective beta1-adrenergic blocker without intrinsic sympathomimetic activity. It has antihypertensive, antianginal, and antiarrhythmic action.
It reduces the stimulating effect on the heart of sympathetic innervation and circulating catecholamines. It has negative chronotropic, dromotropic, bathmotropic, and inotropic effects: it reduces heart rate, inhibits conduction and excitability, and reduces myocardial contractility. Total peripheral vascular resistance at the beginning of beta-blocker use (in the first 24 hours after oral administration) increases (as a result of reciprocal increase in the activity of alpha-adrenergic receptors and elimination of stimulation of beta2-adrenergic receptors), returns to the initial level after 1-3 days, and decreases with long-term use.
The hypotensive effect is associated with a decrease in cardiac output, a decrease in the activity of the renin-angiotensin system (more important for patients with initial hypersecretion of renin), sensitivity of the aortic arch baroreceptors (their activity does not increase in response to a decrease in blood pressure), and an effect on the central nervous system; it is manifested by a decrease in both systolic and diastolic blood pressure, stroke volume, and cardiac output. In average therapeutic doses, it does not affect the tone of peripheral arteries.
The antianginal effect is determined by a decrease in myocardial oxygen demand as a result of a decrease in heart rate (prolongation of diastole and improvement of myocardial perfusion) and contractility, as well as a decrease in myocardial sensitivity to the effects of sympathetic innervation. The decrease in heart rate occurs at rest and during physical exertion. Due to an increase in the end-diastolic pressure in the left ventricle and an increase in the stretching of the ventricular muscle fibers, it may increase oxygen demand, especially in patients with chronic heart failure.
The antiarrhythmic effect is due to the elimination of arrhythmogenic factors (tachycardia, increased activity of the sympathetic nervous system, increased cAMP content, arterial hypertension), a decrease in the rate of spontaneous excitation of the sinus and ectopic pacemakers, and a slowdown in AV conduction. Inhibition of impulse conduction is noted mainly in the antegrade and to a lesser extent in the retrograde directions through the AV node and along additional pathways.
Unlike non-selective beta-blockers, when used in average therapeutic doses, it has a less pronounced effect on organs containing beta2-adrenergic receptors (pancreas, skeletal muscles, smooth muscles of peripheral arteries, bronchi, and uterus) and on carbohydrate metabolism; the severity of the atherogenic effect does not differ from that of propranolol. The negative bathmotropic, chronotropic, inotropic, and dromotropic effects are less pronounced. When used in high doses (more than 100 mg/day), it causes blockade of both subtypes of beta-adrenergic receptors.
The hypotensive effect lasts 24 hours; with regular use, it stabilizes by the end of the 2nd week of treatment. The negative chronotropic effect appears 1 hour after administration, reaches a maximum after 2-4 hours, and lasts up to 24 hours.
Pharmacokinetics
After oral administration, absorption from the gastrointestinal tract is 50-60%, bioavailability is 40-50%. It is practically not metabolized in the body. It poorly penetrates the blood-brain barrier. Plasma protein binding is 6-16%.
T1/2 is 6-9 hours. It is excreted mainly by the kidneys unchanged. Impaired renal function is accompanied mainly by an increase in T1/2 and accumulation: with a creatinine clearance of less than 35 ml/min, T1/2 is 16-27 hours; with a creatinine clearance of less than 15 ml/min, it is more than 27 hours; with anuria, it is prolonged to 144 hours. It is removed during hemodialysis.
In elderly patients, T1/2 increases.
Indications
Arterial hypertension, hypertensive crisis, mitral valve prolapse, hyperkinetic cardiac syndrome of functional origin, neurocirculatory dystonia of the hypertensive type.
Treatment: Coronary artery disease, angina pectoris (exertional, rest, and unstable).
Treatment and prevention: Myocardial infarction (acute phase with stable hemodynamic parameters, secondary prevention).
Arrhythmias (including during general anesthesia, congenital long QT syndrome, myocardial infarction without signs of chronic heart failure, thyrotoxicosis), sinus tachycardia, paroxysmal atrial tachycardia, supraventricular and ventricular extrasystole, supraventricular and ventricular tachycardia, atrial tachyarrhythmia, atrial flutter.
Essential and senile tremor, agitation and tremor in withdrawal syndrome.
As part of complex therapy: Hypertrophic obstructive cardiomyopathy, pheochromocytoma (only together with alpha-blockers), thyrotoxicosis; migraine (prevention).
ICD codes
| ICD-10 code | Indication |
| C74.1 | Malignant neoplasm of adrenal medulla |
| D35.0 | Benign neoplasm of adrenal gland |
| E05 | Thyrotoxicosis [hyperthyroidism] |
| F10.3 | Withdrawal state |
| F45.3 | Somatoform dysfunction of the autonomic nervous system |
| G25.0 | Essential tremor |
| G25.2 | Other specified forms of tremor |
| G43 | Migraine |
| I10 | Essential [primary] hypertension |
| I20 | Angina pectoris |
| I20.0 | Unstable angina |
| I21 | Acute myocardial infarction |
| I34.1 | Prolapse [prolapsing] mitral valve |
| I42.1 | Obstructive hypertrophic cardiomyopathy |
| I45.8 | Other specified conduction disorders |
| I47.1 | Supraventricular tachycardia |
| I47.2 | Ventricular tachycardia |
| I48 | Atrial fibrillation and flutter |
| I49.4 | Other and unspecified premature depolarization |
| I49.8 | Other specified cardiac arrhythmias |
| ICD-11 code | Indication |
| 2D11.Z | Malignant neoplasms of adrenal gland, unspecified |
| 2F37.Y | Other specified benign neoplasm of endocrine glands |
| 2F37.Z | Benign neoplasm of endocrine glands, unspecified |
| 5A02.Z | Thyrotoxicosis, unspecified |
| 6C20.Z | Bodily distress disorder, unspecified |
| 6C40.4Z | Alcohol withdrawal syndrome, unspecified |
| 8A04.0 | Enhanced physiological tremor |
| 8A04.1 | Essential tremor or related tremors |
| 8A04.2 | Rest tremor |
| 8A04.30 | Tremor due to metabolic disorders |
| 8A04.31 | Tremor due to chronic or acute exposure to psychoactive substances |
| 8A04.32 | Tremor due to withdrawal of medicinal products |
| 8A04.33 | Tremor due to certain specified diseases of the central nervous system |
| 8A04.3Z | Secondary tremor, unspecified |
| 8A04.4 | Functional tremor |
| 8A04.Y | Other specified disorders with tremor |
| 8A04.Z | Disorders with tremor, unspecified |
| 8A80.Z | Migraine, unspecified |
| 8A8Z | Headache disorders, unspecified |
| BA00.Z | Essential hypertension, unspecified |
| BA40.0 | Unstable angina |
| BA40.Z | Angina pectoris, unspecified |
| BA41.Z | Acute myocardial infarction, unspecified |
| BB62.Z | Mitral valve prolapse, unspecified |
| BC43.12 | Obstructive hypertrophic cardiomyopathy |
| BC43.1Z | Hypertrophic cardiomyopathy, unspecified |
| BC62 | Accessory pathway |
| BC63.Z | Conduction disorders, unspecified |
| BC65.0 | Long QT syndrome |
| BC65.1 | Brugada syndrome |
| BC65.2 | Short QT syndrome |
| BC65.3 | Early repolarization syndrome |
| BC65.4 | Idiopathic ventricular fibrillation |
| BC65.5 | Catecholaminergic polymorphic ventricular tachycardia |
| BC65.Z | Cardiac arrhythmia associated with genetic anomalies, unspecified |
| BC71.0Z | Ventricular tachycardia, unspecified |
| BC71.Z | Ventricular tachyarrhythmia, unspecified |
| BC81.0 | Ectopic atrial tachycardia |
| BC81.1 | Nodal ectopic tachycardia |
| BC81.20 | CTI [cavotricuspid isthmus]-dependent atrial tachycardia by "macro re-entry" mechanism |
| BC81.21 | Atrial tachycardia by "macro re-entry" mechanism not associated with scar or cavotricuspid isthmus |
| BC81.2Z | Atrial tachycardia by "macro re-entry" mechanism, unspecified |
| BC81.5 | Sinoatrial reentrant tachycardia |
| BC81.6 | Inappropriate sinus tachycardia |
| BC81.7Z | Atrioventricular reentrant tachycardia, unspecified |
| BC81.8 | Atrioventricular nodal reentrant tachycardia |
| BC81.Z | Supraventricular tachyarrhythmia, unspecified |
| BC8Z | Supraventricular arrhythmia, unspecified |
| BC90 | Atrioventricular nodal rhythm |
| BE2Y | Other specified diseases of the circulatory system |
| 8A04.3Y | Other specified secondary tremor |
| 8C0Z | Polyneuropathy, unspecified |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Tablets
The dose is set individually. The usual dose for adults is orally, at the beginning of treatment, 25-50 mg once a day. If necessary, the dose is gradually increased. In case of impaired renal function in patients with a creatinine clearance of 15-35 ml/min – 50 mg/day; with a creatinine clearance of less than 15 ml/min – 50 mg every other day.
Maximum dose for adults when taken orally is 200 mg/day in 1 or 2 doses.
Adverse Reactions
From the cardiovascular system in some cases – bradycardia, arterial hypotension, AV conduction disorders, appearance of symptoms of heart failure.
From the digestive system at the beginning of therapy, nausea, constipation, diarrhea, dry mouth are possible.
From the nervous system at the beginning of therapy, fatigue, dizziness, depression, mild headache, sleep disturbances, feeling of cold and paresthesia in the extremities, decreased patient reaction speed are possible.
From the organ of vision decreased secretion of tear fluid, conjunctivitis.
From the endocrine system decreased potency, hypoglycemic conditions in patients with diabetes mellitus.
From the respiratory system in predisposed patients – appearance of symptoms of bronchial obstruction.
Allergic reactions skin itching.
Other increased sweating, skin redness.
Contraindications
AV block of II and III degree, sinoatrial block, sick sinus syndrome, bradycardia (heart rate less than 40 beats/min), arterial hypotension (in case of use in myocardial infarction, systolic blood pressure less than 100 mm Hg), cardiogenic shock, chronic heart failure stage IIB-III, acute heart failure, Prinzmetal’s angina, lactation period, simultaneous use of MAO inhibitors, hypersensitivity to atenolol.
Use in Pregnancy and Lactation
Atenolol crosses the placental barrier, so use during pregnancy is possible only if the intended benefit to the mother outweighs the possible risk to the fetus.
Atenolol is excreted in breast milk, so if it is necessary to use during lactation, it is recommended to stop breastfeeding.
Use in Hepatic Impairment
Should be used with caution in hepatic insufficiency.
Use in Renal Impairment
Should be used with caution in chronic renal failure. In case of impaired renal function in patients with a creatinine clearance of 15-35 ml/min – 50 mg/day; with a creatinine clearance of less than 15 ml/min – 50 mg every other day.
Pediatric Use
Should be used with caution in pediatrics (efficacy and safety have not been established).
Geriatric Use
Should be used with caution in elderly patients.
Special Precautions
Should be used with caution in diabetes mellitus, COPD (including bronchial asthma, pulmonary emphysema), metabolic acidosis, hypoglycemia; history of allergic reactions, chronic heart failure (compensated), obliterating diseases of peripheral arteries (intermittent claudication, Raynaud’s syndrome), pheochromocytoma, hepatic insufficiency, chronic renal failure, myasthenia gravis, thyrotoxicosis, depression (including history), psoriasis, during pregnancy, in elderly patients, in pediatrics (efficacy and safety have not been established).
When using atenolol, a decrease in tear fluid production is possible, which is important for patients using contact lenses.
Discontinuation of atenolol after a long course of treatment should be carried out gradually under medical supervision.
When discontinuing the combined use of atenolol and clonidine, treatment with clonidine should be continued for several more days after the withdrawal of atenolol, otherwise severe arterial hypertension may occur.
If it is necessary to perform inhalation anesthesia in patients receiving Atenolol, it is necessary to stop taking atenolol several days before anesthesia or to select an anesthetic agent with minimal negative inotropic effect.
Effect on the ability to drive vehicles and mechanisms
In patients whose activities require increased concentration, the issue of outpatient use of atenolol should be decided only after assessing the individual reaction.
Drug Interactions
With simultaneous use of diuretics, the antihypertensive effect is enhanced.
With simultaneous use of agents for inhalation anesthesia, the risk of enhancing the cardiodepressive effect and developing arterial hypotension increases.
There are reports of the development of bradycardia and arterial hypotension with simultaneous use of alcuronium chloride.
With simultaneous use of verapamil, the negative inotropic effect is enhanced, bradycardia, bradyarrhythmia, and severe conduction disturbances develop; cases of postural hypotension, dizziness, left ventricular failure, and lethargy have been described. Under the influence of verapamil, the pharmacokinetic parameters of atenolol do not change significantly, although a case of an increase in the AUC of atenolol has been described.
With simultaneous use of disopyramide, Css increases, the clearance of disopyramide decreases, and conduction disturbances are possible.
With simultaneous use of dipyridamole, a case of the development of bradycardia and then asystole has been described (during an ECG test with dipyridamole in a patient receiving Atenolol).
With simultaneous use of indomethacin, naproxen, and other NSAIDs, a decrease in the antihypertensive effect of atenolol is possible, which is to a certain extent due to a violation (under the influence of NSAIDs) of the synthesis in the kidneys and release into the bloodstream of prostaglandins PGA and PGE, which have a strong vasodilating effect on peripheral arterioles.
With simultaneous use of insulin, an increase in blood pressure is possible.
With simultaneous use of clonidine, an additive hypotensive effect, sedative effect, and dry mouth are possible.
With simultaneous use of caffeine, a decrease in the effectiveness of atenolol is possible.
With simultaneous use of nizatidine, a case of enhanced cardiodepressive effect has been described.
With simultaneous use of nifedipine, cases of severe arterial hypotension and heart failure have been described, which may be due to an increase in the inhibitory effect of nifedipine on the myocardium.
With simultaneous use of orlistat, the antihypertensive effect of atenolol decreases, which can lead to a significant increase in blood pressure and the development of a hypertensive crisis.
With simultaneous use of prenylamine, an increase in the QT interval is possible.
With simultaneous use of chlorthalidone, the antihypertensive effect is enhanced.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Rx Only
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical DisclaimerBrand (or Active Substance), Marketing Authorisation Holder, Dosage Form
Tablets 50 mg: 20, 30, 40 or 50 pcs.
Marketing Authorization Holder
Biopharm Pravo-Alpha, LLC (Russia)
Dosage Form
 |
Atenolol tablets | Tablets 50 mg: 20, 30, 40 or 50 pcs. |
Dosage Form, Packaging, and Composition
| Tablets | 1 tab. |
| Atenolol | 50 mg |
10 pcs. – blister packs (3) – cardboard boxes.
10 pcs. – blister packs (5) – cardboard boxes.
20 pcs. – blister packs (1) – cardboard packs.
20 pcs. – blister packs (2) – cardboard packs.
30 pcs. – dark glass jars (1) – cardboard packs.
50 pcs. – dark glass jars (1) – cardboard packs.
Tablets 100 mg: 20, 30, 40 or 50 pcs.
Marketing Authorization Holder
Biopharm Pravo-Alpha, LLC (Russia)
Dosage Form
|
Atenolol tablets | Tablets 100 mg: 20, 30, 40 or 50 pcs. |
Dosage Form, Packaging, and Composition
| Tablets | 1 tab. |
| Atenolol | 100 mg |
10 pcs. – contour cell packs (3) – cardboard boxes.
10 pcs. – contour cell packs (5) – cardboard boxes.
20 pcs. – contour cell packs (1) – cardboard packs.
20 pcs. – contour cell packs (2) – cardboard packs.
30 pcs. – dark glass jars (1) – cardboard packs.
50 pcs. – dark glass jars (1) – cardboard packs.
Tablets 50 mg: 20, 30, 40 or 50 pcs.
Marketing Authorization Holder
Biopharma, CJS (Russia)
Dosage Form
|
Atenolol tablets | Tablets 50 mg: 20, 30, 40 or 50 pcs. |
Dosage Form, Packaging, and Composition
| Tablets | 1 tab. |
| Atenolol | 50 mg |
10 pcs. – contour cell packs (3) – cardboard boxes.
10 pcs. – contour cell packs (5) – cardboard boxes.
20 pcs. – contour cell packs (1) – cardboard packs.
20 pcs. – contour cell packs (2) – cardboard packs.
30 pcs. – dark glass jars (1) – cardboard packs.
50 pcs. – dark glass jars (1) – cardboard packs.
Tablets 100 mg: 20, 30, 40 or 50 pcs.
Marketing Authorization Holder
Biopharma, CJS (Russia)
Dosage Form
|
Atenolol tablets | Tablets 100 mg: 20, 30, 40 or 50 pcs. |
Dosage Form, Packaging, and Composition
| Tablets | 1 tab. |
| Atenolol | 100 mg |
10 pcs. – contour cell packs (3) – cardboard boxes.
10 pcs. – contour cell packs (5) – cardboard boxes.
20 pcs. – contour cell packs (1) – cardboard packs.
20 pcs. – contour cell packs (2) – cardboard packs.
30 pcs. – dark glass jars (1) – cardboard packs.
50 pcs. – dark glass jars (1) – cardboard packs.
Tablets 50 mg: 20, 30, 40 or 50 pcs.
Marketing Authorization Holder
Bryntsalov-A, JSC (Russia)
Dosage Form
|
Atenolol tablets | Tablets 50 mg: 20, 30, 40 or 50 pcs. |
Dosage Form, Packaging, and Composition
| Tablets | 1 tab. |
| Atenolol | 50 mg |
10 pcs. – contour cell packs (3) – cardboard boxes.
10 pcs. – contour cell packs (5) – cardboard boxes.
20 pcs. – contour cell packs (1) – cardboard packs.
20 pcs. – contour cell packs (2) – cardboard packs.
30 pcs. – dark glass jars (1) – cardboard packs.
50 pcs. – dark glass jars (1) – cardboard packs.
Tablets 100 mg: 20, 30, 40 or 50 pcs.
Marketing Authorization Holder
Bryntsalov-A, JSC (Russia)
Dosage Form
|
Atenolol tablets | Tablets 100 mg: 20, 30, 40 or 50 pcs. |
Dosage Form, Packaging, and Composition
| Tablets | 1 tab. |
| Atenolol | 100 mg |
10 pcs. – contour cell packs (3) – cardboard boxes.
10 pcs. – contour cell packs (5) – cardboard boxes.
20 pcs. – contour cell packs (1) – cardboard packs.
20 pcs. – contour cell packs (2) – cardboard packs.
30 pcs. – dark glass jars (1) – cardboard packs.
50 pcs. – dark glass jars (1) – cardboard packs.
Tablets 50 mg: 20, 30, 40 or 50 pcs.
Marketing Authorization Holder
Yekaterinburg Pharmaceutical Company, LLC (Russia)
Dosage Form
|
Atenolol tablets | Tablets 50 mg: 20, 30, 40 or 50 pcs. |
Dosage Form, Packaging, and Composition
| Tablets | 1 tab. |
| Atenolol | 50 mg |
10 pcs. – contour cell packs (3) – cardboard boxes.
10 pcs. – contour cell packs (5) – cardboard boxes.
20 pcs. – contour cell packs (1) – cardboard packs.
20 pcs. – contour cell packs (2) – cardboard packs.
30 pcs. – dark glass jars (1) – cardboard packs.
50 pcs. – dark glass jars (1) – cardboard packs.
Tablets 100 mg: 20, 30, 40 or 50 pcs.
Marketing Authorization Holder
Yekaterinburg Pharmaceutical Company, LLC (Russia)
Dosage Form
|
Atenolol tablets | Tablets 100 mg: 20, 30, 40 or 50 pcs. |
Dosage Form, Packaging, and Composition
| Tablets | 1 tab. |
| Atenolol | 100 mg |
10 pcs. – contour cell packs (3) – cardboard boxes.
10 pcs. – contour cell packs (5) – cardboard boxes.
20 pcs. – contour cell packs (1) – cardboard packs.
20 pcs. – contour cell packs (2) – cardboard packs.
30 pcs. – dark glass jars (1) – cardboard packs.
50 pcs. – dark glass jars (1) – cardboard packs.
Tablets 50 mg: 20, 30, 40 or 50 pcs.
Marketing Authorization Holder
Interpharma, LLC (Russia)
Dosage Form
|
Atenolol tablets | Tablets 50 mg: 20, 30, 40 or 50 pcs. |
Dosage Form, Packaging, and Composition
| Tablets | 1 tab. |
| Atenolol | 50 mg |
10 pcs. – contour cell packs (3) – cardboard boxes.
10 pcs. – contour cell packs (5) – cardboard boxes.
20 pcs. – contour cell packs (1) – cardboard packs.
20 pcs. – contour cell packs (2) – cardboard packs.
30 pcs. – dark glass jars (1) – cardboard packs.
50 pcs. – dark glass jars (1) – cardboard packs.
Tablets 100 mg: 20, 30, 40 or 50 pcs.
Marketing Authorization Holder
Interpharma, LLC (Russia)
Dosage Form
|
Atenolol tablets | Tablets 100 mg: 20, 30, 40 or 50 pcs. |
Dosage Form, Packaging, and Composition
| Tablets | 1 tab. |
| Atenolol | 100 mg |
10 pcs. – contour cell packs (3) – cardboard boxes.
10 pcs. – contour cell packs (5) – cardboard boxes.
20 pcs. – contour cell packs (1) – cardboard packs.
20 pcs. – contour cell packs (2) – cardboard packs.
30 pcs. – dark glass jars (1) – cardboard packs.
50 pcs. – dark glass jars (1) – cardboard packs.
Tablets 50 mg: 20, 30, 40 or 50 pcs.
Marketing Authorization Holder
Organika, JSC (Russia)
Dosage Form
|
Atenolol tablets | Tablets 50 mg: 20, 30, 40 or 50 pcs. |
Dosage Form, Packaging, and Composition
| Tablets | 1 tab. |
| Atenolol | 50 mg |
10 pcs. – contour cell packs (3) – cardboard boxes.
10 pcs. – contour cell packs (5) – cardboard boxes.
20 pcs. – contour cell packs (1) – cardboard packs.
20 pcs. – contour cell packs (2) – cardboard packs.
30 pcs. – dark glass jars (1) – cardboard packs.
50 pcs. – dark glass jars (1) – cardboard packs.
Tablets 100 mg: 20, 30, 40 or 50 pcs.
Marketing Authorization Holder
Organika, JSC (Russia)
Dosage Form
|
Atenolol tablets | Tablets 100 mg: 20, 30, 40 or 50 pcs. |
Dosage Form, Packaging, and Composition
| Tablets | 1 tab. |
| Atenolol | 100 mg |
10 pcs. – contour cell packs (3) – cardboard boxes.
10 pcs. – contour cell packs (5) – cardboard boxes.
20 pcs. – contour cell packs (1) – cardboard packs.
20 pcs. – contour cell packs (2) – cardboard packs.
30 pcs. – dark glass jars (1) – cardboard packs.
50 pcs. – dark glass jars (1) – cardboard packs.
Tablets 50 mg: 20, 30, 40 or 50 pcs.
Marketing Authorization Holder
STI-Med-Sorb, PJSC (Russia)
Dosage Form
|
Atenolol tablets | Tablets 50 mg: 20, 30, 40 or 50 pcs. |
Dosage Form, Packaging, and Composition
| Tablets | 1 tab. |
| Atenolol | 50 mg |
10 pcs. – contour cell packs (3) – cardboard boxes.
10 pcs. – contour cell packs (5) – cardboard boxes.
20 pcs. – contour cell packs (1) – cardboard packs.
20 pcs. – contour cell packs (2) – cardboard packs.
30 pcs. – dark glass jars (1) – cardboard packs.
50 pcs. – dark glass jars (1) – cardboard packs.
Tablets 100 mg: 20, 30, 40 or 50 pcs.
Marketing Authorization Holder
STI-Med-Sorb, PJSC (Russia)
Dosage Form
|
Atenolol tablets | Tablets 100 mg: 20, 30, 40 or 50 pcs. |
Dosage Form, Packaging, and Composition
| Tablets | 1 tab. |
| Atenolol | 100 mg |
10 pcs. – contour cell packs (3) – cardboard boxes.
10 pcs. – contour cell packs (5) – cardboard boxes.
20 pcs. – contour cell packs (1) – cardboard packs.
20 pcs. – contour cell packs (2) – cardboard packs.
30 pcs. – dark glass jars (1) – cardboard packs.
50 pcs. – dark glass jars (1) – cardboard packs.
Tablets 50 mg: 20, 30, 40 or 50 pcs.
Marketing Authorization Holder
Usolye-Sibirskiy Chemical and Pharmaceutical Combine, JSC (Russia)
Dosage Form
|
Atenolol tablets | Tablets 50 mg: 20, 30, 40 or 50 pcs. |
Dosage Form, Packaging, and Composition
| Tablets | 1 tab. |
| Atenolol | 50 mg |
10 pcs. – contour cell packs (3) – cardboard boxes.
10 pcs. – contour cell packs (5) – cardboard boxes.
20 pcs. – contour cell packs (1) – cardboard packs.
20 pcs. – contour cell packs (2) – cardboard packs.
30 pcs. – dark glass jars (1) – cardboard packs.
50 pcs. – dark glass jars (1) – cardboard packs.
Tablets 100 mg: 20, 30, 40 or 50 pcs.
Marketing Authorization Holder
Usolye-Sibirskiy Chemical and Pharmaceutical Combine, JSC (Russia)
Dosage Form
|
Atenolol tablets | Tablets 100 mg: 20, 30, 40 or 50 pcs. |
Dosage Form, Packaging, and Composition
| Tablets | 1 tab. |
| Atenolol | 100 mg |
10 pcs. – contour cell packs (3) – cardboard boxes.
10 pcs. – contour cell packs (5) – cardboard boxes.
20 pcs. – contour cell packs (1) – cardboard packs.
20 pcs. – contour cell packs (2) – cardboard packs.
30 pcs. – dark glass jars (1) – cardboard packs.
50 pcs. – dark glass jars (1) – cardboard packs.
Tablets 50 mg: 20, 30, 40 or 50 pcs.
Marketing Authorization Holder
Pharmsintez OJSC (Russia)
Dosage Form
|
Atenolol tablets | Tablets 50 mg: 20, 30, 40 or 50 pcs. |
Dosage Form, Packaging, and Composition
| Tablets | 1 tab. |
| Atenolol | 50 mg |
10 pcs. – contour cell packs (3) – cardboard boxes.
10 pcs. – contour cell packs (5) – cardboard boxes.
20 pcs. – contour cell packs (1) – cardboard packs.
20 pcs. – contour cell packs (2) – cardboard packs.
30 pcs. – dark glass jars (1) – cardboard packs.
50 pcs. – dark glass jars (1) – cardboard packs.
Tablets 100 mg: 20, 30, 40 or 50 pcs.
Marketing Authorization Holder
Pharmsintez OJSC (Russia)
Dosage Form
|
Atenolol tablets | Tablets 100 mg: 20, 30, 40 or 50 pcs. |
Dosage Form, Packaging, and Composition
| Tablets | 1 tab. |
| Atenolol | 100 mg |
10 pcs. – contour cell packs (3) – cardboard boxes.
10 pcs. – contour cell packs (5) – cardboard boxes.
20 pcs. – contour cell packs (1) – cardboard packs.
20 pcs. – contour cell packs (2) – cardboard packs.
30 pcs. – dark glass jars (1) – cardboard packs.
50 pcs. – dark glass jars (1) – cardboard packs.
Film-coated tablets, 25 mg: 30 pcs.
Marketing Authorization Holder
Belupo, Pharmaceuticals & Cosmetics d.d. (Croatia)
Dosage Form
|
Atenolol Belupo | Film-coated tablets, 25 mg: 30 pcs. |
Dosage Form, Packaging, and Composition
Film-coated tablets white, round, biconvex.
| 1 tab. | |
| Atenolol | 25 mg |
Excipients: microcrystalline cellulose, lactose monohydrate, povidone, corn starch, talc, colloidal silicon dioxide, croscarmellose sodium, magnesium stearate.
Shell composition: hypromellose 5 cps, hypromellose 15 cps, talc, titanium dioxide, disodium edetate dihydrate.
30 pcs. – blisters (1) – cardboard packs.
Film-coated tablets, 50 mg: 30 pcs.
Marketing Authorization Holder
Belupo, Pharmaceuticals & Cosmetics d.d. (Croatia)
Dosage Form
|
Atenolol Belupo | Film-coated tablets, 50 mg: 30 pcs. |
Dosage Form, Packaging, and Composition
Film-coated tablets white, round, biconvex, with a score on one side.
| 1 tab. | |
| Atenolol | 50 mg |
Excipients: microcrystalline cellulose, lactose monohydrate, povidone, corn starch, talc, colloidal silicon dioxide, croscarmellose sodium, magnesium stearate.
Shell composition: hypromellose 5 cps, hypromellose 15 cps, talc, titanium dioxide, disodium edetate dihydrate.
30 pcs. – blisters (1) – cardboard packs.
Film-coated tablets, 100 mg: 14 or 28 pcs.
Marketing Authorization Holder
Belupo, Pharmaceuticals & Cosmetics d.d. (Croatia)
Dosage Form
|
Atenolol Belupo | Film-coated tablets, 100 mg: 14 or 28 pcs. |
Dosage Form, Packaging, and Composition
Film-coated tablets white, round, biconvex, with a score on one side.
| 1 tab. | |
| Atenolol | 100 mg |
Excipients: microcrystalline cellulose, lactose monohydrate, povidone, corn starch, talc, colloidal silicon dioxide, croscarmellose sodium, magnesium stearate.
Shell composition: hypromellose 5 cps, hypromellose 15 cps, talc, titanium dioxide, disodium edetate dihydrate, carnauba wax.
14 pcs. – blisters (1) – cardboard packs.
14 pcs. – blisters (2) – cardboard packs.
Film-coated tablets, 50 mg: 30 pcs.
Marketing Authorization Holder
Nycomed Danmark A/S (Denmark)
Dosage Form
|
Atenolol Nycomed | Film-coated tablets, 50 mg: 30 pcs. |
Dosage Form, Packaging, and Composition
Film-coated tablets white, capsule-shaped, biconvex, with a break line and embossing "AB55".
| 1 tab. | |
| Atenolol | 50 mg |
Excipients: gelatin – 2.1 mg, sodium lauryl sulfate – 3.3 mg, magnesium stearate – 5 mg, corn starch – 60 mg, magnesium carbonate – 87.5 mg.
Shell composition: propylene glycol – about 400 mcg, titanium dioxide – about 800 mcg, talc – about 800 mcg, hypromellose E15 – about 2.1 mg.
30 pcs. – plastic bottles.
Film-coated tablets, 100 mg: 30 pcs.
Marketing Authorization Holder
Nycomed Danmark A/S (Denmark)
Dosage Form
|
Atenolol Nycomed | Film-coated tablets, 100 mg: 30 pcs. |
Dosage Form, Packaging, and Composition
Film-coated tablets white, capsule-shaped, biconvex, with a break line and embossing "AB57".
| 1 tab. | |
| Atenolol | 100 mg |
Excipients: gelatin – 4.2 mg, sodium lauryl sulfate – 6.6 mg, magnesium stearate – 10 mg, corn starch – 120 mg, magnesium carbonate – 175 mg.
Shell composition: propylene glycol – about 800 mcg, titanium dioxide – about 1.7 mg, talc – about 1.7 mg, hypromellose E15 – about 4.2 mg.
30 pcs. – plastic bottles.
Tablets 50 mg: 20, 30, 50 or 100 pcs.
Marketing Authorization Holder
Stada Arzneimittel, AG (Germany)
Manufactured By
Allphamed Pharbil Arzneimittel, GmbH (Germany)
Dosage Form
|
Atenolol Stada® | Tablets 50 mg: 20, 30, 50 or 100 pcs. |
Dosage Form, Packaging, and Composition
Tablets white, biconvex, with a break line and the inscription "C24" on the upper part of the tablet.
| 1 tab. | |
| Atenolol | 50 mg |
10 pcs. – blisters (2) – cardboard packs.
10 pcs. – blisters (3) – cardboard packs.
10 pcs. – blisters (5) – cardboard packs.
10 pcs. – blisters (10) – cardboard packs.
Tablets 100 mg: 20, 30, 50 or 100 pcs.
Marketing Authorization Holder
Stada Arzneimittel, AG (Germany)
Manufactured By
Allphamed Pharbil Arzneimittel, GmbH (Germany)
Dosage Form
|
Atenolol Stada® | Tablets 100 mg: 20, 30, 50 or 100 pcs. |
Dosage Form, Packaging, and Composition
Tablets white, biconvex, with a break line and the inscription "C25" on the upper part of the tablet.
| 1 tab. | |
| Atenolol | 100 mg |
10 pcs. – blisters (2) – cardboard packs.
10 pcs. – blisters (3) – cardboard packs.
10 pcs. – blisters (5) – cardboard packs.
10 pcs. – blisters (10) – cardboard packs.
Tablets 50 mg: 30 pcs.
Marketing Authorization Holder
Agio Pharmaceuticals, Ltd. (India)
Dosage Form
|
Atenolol-Agio | Tablets 50 mg: 30 pcs. |
Dosage Form, Packaging, and Composition
| Tablets | 1 tab. |
| Atenolol | 50 mg |
10 pcs. – contour cell packs (3) – cardboard packs.
30 pcs. – polypropylene containers (1) – cardboard packs.
Tablets 100 mg: 30 pcs.
Marketing Authorization Holder
Agio Pharmaceuticals, Ltd. (India)
Dosage Form
|
Atenolol-Agio | Tablets 100 mg: 30 pcs. |
Dosage Form, Packaging, and Composition
| Tablets | 1 tab. |
| Atenolol | 100 mg |
10 pcs. – contour cell packs (3) – cardboard packs.
30 pcs. – polypropylene containers (1) – cardboard packs.
Tablets 50 mg: 30 pcs.
Marketing Authorization Holder
Akrikhin Chemical and Pharmaceutical Plant, JSC (Russia)
Dosage Form
|
Atenolol-Akri® | Tablets 50 mg: 30 pcs. |
Dosage Form, Packaging, and Composition
| Tablets | 1 tab. |
| Atenolol | 50 mg |
10 pcs. – contour cell packs (3) – cardboard packs.
Tablets 100 mg: 30 pcs.
Marketing Authorization Holder
Akrikhin Chemical and Pharmaceutical Plant, JSC (Russia)
Dosage Form
|
Atenolol-Akri® | Tablets 100 mg: 30 pcs. |
Dosage Form, Packaging, and Composition
| Tablets | 1 tab. |
| Atenolol | 100 mg |
10 pcs. – contour cell packs (3) – cardboard packs.
Film-coated tablets, 25 mg: 14, 20, 28, 30, 50, or 100 pcs.
Marketing Authorization Holder
Ratiopharm, GmbH (Germany)
Dosage Form
|
Atenolol-Ratiopharm | Film-coated tablets, 25 mg: 14, 20, 28, 30, 50, or 100 pcs. |
Dosage Form, Packaging, and Composition
Film-coated tablets white or almost white, round, biconvex, smooth on one side, with a break line on the other.
| 1 tab. | |
| Atenolol | 25 mg |
Excipients: microcrystalline cellulose, magnesium carbonate, corn starch, sodium lauryl sulfate, magnesium stearate, gelatin, hypromellose, titanium dioxide, glycerol.
10 pcs. – blisters (2) – cardboard packs.
10 pcs. – blisters (3) – cardboard packs.
10 pcs. – blisters (5) – cardboard packs.
10 pcs. – blisters (10) – cardboard packs.
14 pcs. – polyethylene bottles (1) – cardboard packs.
28 pcs. – polyethylene bottles (1) – cardboard packs.
Film-coated tablets, 50 mg: 14, 20, 28, 30, 50, or 100 pcs.
Marketing Authorization Holder
Ratiopharm, GmbH (Germany)
Dosage Form
|
Atenolol-Ratiopharm | Film-coated tablets, 50 mg: 14, 20, 28, 30, 50, or 100 pcs. |
Dosage Form, Packaging, and Composition
Film-coated tablets white or almost white, round, biconvex, smooth on one side, with a break line on the other.
| 1 tab. | |
| Atenolol | 50 mg |
Excipients: microcrystalline cellulose, magnesium carbonate, corn starch, sodium lauryl sulfate, magnesium stearate, gelatin, hypromellose, titanium dioxide, glycerol.
10 pcs. – blisters (2) – cardboard packs.
10 pcs. – blisters (3) – cardboard packs.
10 pcs. – blisters (5) – cardboard packs.
10 pcs. – blisters (10) – cardboard packs.
14 pcs. – polyethylene bottles (1) – cardboard packs.
28 pcs. – polyethylene bottles (1) – cardboard packs.
Film-coated tablets, 100 mg: 14, 20, 28, 30, 50, or 100 pcs.
Marketing Authorization Holder
Ratiopharm, GmbH (Germany)
Dosage Form
|
Atenolol-Ratiopharm | Film-coated tablets, 100 mg: 14, 20, 28, 30, 50, or 100 pcs. |
Dosage Form, Packaging, and Composition
Film-coated tablets white or almost white, round, biconvex, smooth on one side, with a break line on the other.
| 1 tab. | |
| Atenolol | 100 mg |
Excipients: microcrystalline cellulose, magnesium carbonate, corn starch, sodium lauryl sulfate, magnesium stearate, gelatin, hypromellose, titanium dioxide, glycerol.
10 pcs. – blisters (2) – cardboard packs.
10 pcs. – blisters (3) – cardboard packs.
10 pcs. – blisters (5) – cardboard packs.
10 pcs. – blisters (10) – cardboard packs.
14 pcs. – polyethylene bottles (1) – cardboard packs.
28 pcs. – polyethylene bottles (1) – cardboard packs.
Tablets 50 mg: 30 pcs.
Tablets 100 mg: 14 pcs.
Marketing Authorization Holder
Pliva Hrvatska, d.o.o. (Croatia)
Dosage Forms
|
Atenolol-Teva | Tablets 50 mg: 30 pcs. |
| Tablets 100 mg: 14 pcs. |
Dosage Form, Packaging, and Composition
Tablets white or almost white, uniform or with slight marbling, round, with a score on one side and an engraving (stylized letter "P" – PLIVA logo) on the other.
| 1 tab. | |
| Atenolol | 50 mg |
Excipients: microcrystalline cellulose (type 102), carbomer (carbopol 974P), sodium lauryl sulfate, calcium hydrogen phosphate dihydrate, croscarmellose sodium (type A), colloidal silicon dioxide, talc, hydrogenated vegetable oil (type I), magnesium stearate.
10 pcs. – blisters (3) – cardboard packs×.
× protective stickers may be additionally applied to the pack.
Tablets white or almost white, uniform or with slight marbling, round, with a score on one side and an engraving "PLIVA" on the other.
| 1 tab. | |
| Atenolol | 100 mg |
Excipients: microcrystalline cellulose (type 102), carbomer (carbopol 974P), sodium lauryl sulfate, calcium hydrogen phosphate dihydrate, croscarmellose sodium (type A), colloidal silicon dioxide, talc, hydrogenated vegetable oil (type I), magnesium stearate.
14 pcs. – blisters (1) – cardboard packs×.
× protective stickers may be additionally applied to the pack.
Tablets 100 mg: 10, 20, 30, 40, 50, or 60 pcs.
Marketing Authorization Holder
Uralbiopharm, JSC (Russia)
Dosage Form
|
Atenolol-UBF | Tablets 100 mg: 10, 20, 30, 40, 50, or 60 pcs. |
Dosage Form, Packaging, and Composition
| Tablets | 1 tab. |
| Atenolol | 100 mg |
10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (3) (foil/PVC) – cardboard packs.
10 pcs. – contour cell packs (PVC/paper) (3) – cardboard packs.
10 pcs. – contour cell packs (5) – cardboard packs.
10 pcs. – contour cell packs (6) – cardboard packs.
20 pcs. – polymer jars (1) – cardboard packs.
30 pcs. – polymer jars (1) – cardboard packs.
40 pcs. – polymer jars (1) – cardboard packs.
50 pcs. – polymer jars (1) – cardboard packs.
60 pcs. – polymer jars (1) – cardboard packs.
![Atenolol tablets [Tablets] 1](https://www.medixlife.com/wp-content/uploads/Medixlife_favi_512.png "Atenolol tablets [Tablets] 2")